134 related articles for article (PubMed ID: 1397055)
1. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis.
Vrána O; Kiseleva VI; Poverenny AM; Brabec V
Eur J Pharmacol; 1992 May; 226(1):5-13. PubMed ID: 1397055
[TBL] [Abstract][Full Text] [Related]
2. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
3. Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA.
Pérez C; Leng M; Malinge JM
Nucleic Acids Res; 1997 Feb; 25(4):896-903. PubMed ID: 9016644
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal antibodies elicited against trans-diamminedichloroplatinum(II)-modified DNA and their application in nonradioactive hybridization experiments.
Brabec V; Vrana O; Kiseleva VI; Poverenny AM
Eur J Biochem; 1991 Nov; 201(3):723-30. PubMed ID: 1935966
[TBL] [Abstract][Full Text] [Related]
5. Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA.
Bernal-Méndez E; Boudvillain M; González-Vilchez F; Leng M
Biochemistry; 1997 Jun; 36(24):7281-7. PubMed ID: 9200676
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
[TBL] [Abstract][Full Text] [Related]
7. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.
Payet D; Gaucheron F; Sip M; Leng M
Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).
Sundquist WI; Lippard SJ; Stollar BD
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320
[TBL] [Abstract][Full Text] [Related]
10. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
Kaspárková J; Brabec V
Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
[TBL] [Abstract][Full Text] [Related]
11. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N
Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899
[TBL] [Abstract][Full Text] [Related]
12. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
Poirier MC; Lippard SJ; Zwelling LA; Ushay HM; Kerrigan D; Thill CC; Santella RM; Grunberger D; Yuspa SH
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6443-7. PubMed ID: 6959129
[TBL] [Abstract][Full Text] [Related]
13. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
[TBL] [Abstract][Full Text] [Related]
14. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
Cohen SM; Mikata Y; He Q; Lippard SJ
Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
[TBL] [Abstract][Full Text] [Related]
15. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II).
Bellon SF; Coleman JH; Lippard SJ
Biochemistry; 1991 Aug; 30(32):8026-35. PubMed ID: 1868076
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM
Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564
[TBL] [Abstract][Full Text] [Related]
17. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
18. Binding of cis- and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies.
Sundquist WI; Lippard SJ; Stollar BD
Biochemistry; 1986 Apr; 25(7):1520-4. PubMed ID: 3707890
[TBL] [Abstract][Full Text] [Related]
19. Reaction of nucleic acids with cis-diamminedichloroplatinum(II): interstrand cross-links.
Rahmouni A; Leng M
Biochemistry; 1987 Nov; 26(23):7229-34. PubMed ID: 3427071
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Terheggen PM; Floot BG; Lempers EL; van Tellingen O; Begg AC; den Engelse L
Cancer Chemother Pharmacol; 1991; 28(3):185-91. PubMed ID: 1855275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
